Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition ...

In seeking new antibiotic sources, researchers have turned to an unlikely source: a whiffy frog known as Odorrana andersonii.

Charles River Laboratories International, Inc. CRL and Valo Health, Inc. recently announced an advanced product candidate for the treatment of different forms of lupus and other autoimmune indications ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared Altesa's new Investigational New Drug (IND) application for vapendavir for the treatment of rhinovirus infections in ...

Among patients with uncontrolled hypertension, the investigational drug ... very important to us to study this drug in this population that really needs new options for controlling blood pressure." ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, ...